Aprea Therapeutics (NASDAQ:APRE) Earns Outperform Rating from Wedbush
Aprea Therapeutics (NASDAQ:APRE – Get Free Report)‘s stock had its “outperform” rating reaffirmed by equities research analysts at Wedbush in a note issued to investors on Tuesday,RTT News reports. They presently have a $11.00 price objective on the stock. Wedbush’s price target indicates a potential upside of 391.07% from the company’s current price. Separately, HC […]
Aprea Therapeutics (NASDAQ:APRE – Get Free Report)‘s stock had its “outperform” rating reaffirmed by equities research analysts at Wedbush in a note issued to investors on Tuesday,RTT News reports. They presently have a $11.00 price objective on the stock. Wedbush’s price target indicates a potential upside of 391.07% from the company’s current price. Separately, HC […]
